Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.

The Korean journal of internal medicine - 1 Mar 2018

Yim Eunjung, An Ho Jung, Cho Uiju, Kim Youngwoo, Kim Seung Hoon, Choi Yeon-Geun, Shim Byoung Yong

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 27384439
DOI: 10.3904/kjim.2015.295
PMCID: PMC5840584

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.PMID 27384439Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Semantic proximity Read ↗

Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.Semantic proximity Read ↗

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Semantic proximity Read ↗

Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.Semantic proximity Read ↗

Secondary KIT mutations: the GIST of drug resistance and sensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.